Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors

NCT00036959 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00036959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2002
Completion date
February 28, 2010
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, childhood germ cell tumor, extragonadal germ cell tumor, kidney cancer, liver cancer, neuroblastoma, ovarian cancer, sarcoma, unspecified childhood solid tumor, protocol specific